Search

Author/Creator Miles, David

41. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Issue 4 (April 2020)

Authors:
Swain, Sandra M; Miles, David; Kim, Sung-Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma; Knott, Adam; Restuccia, Eleonora; Benyunes, Mark C; Cortés, Javier
Journal:
Lancet oncology
Issue:
Volume 21:Issue 4(2020)
Page Start:
519
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

46. Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA. (28th May 2014)

Authors:
Swain, Sandra M.; Im, Young-Hyuck; Im, Seock-Ah; Chan, Valorie; Miles, David; Knott, Adam; Clark, Emma; Ross, Graham; Baselga, José
Journal:
Oncologist
Issue:
Volume 19:Number 7(2014)
Page Start:
693
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

47. Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA. (28th May 2014)

Authors:
Swain, Sandra M.; Im, Young‐Hyuck; Im, Seock‐Ah; Chan, Valorie; Miles, David; Knott, Adam; Clark, Emma; Ross, Graham; Baselga, José
Journal:
Oncologist
Issue:
Volume 19:Number 7(2014)
Page Start:
693
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗